Shattuck Labs, Inc. (STTK)
$
0.77
-0.05 (-6.49%)
Key metrics
Financial statements
Free cash flow per share
-1.1075
Market cap
37.1 Million
Price to sales ratio
1.9422
Debt to equity
0.0335
Current ratio
9.0776
Income quality
0.7986
Average inventory
0
ROE
-0.7969
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Shattuck Labs, Inc. is a clinical-stage biotechnology company that focuses on developing therapeutics for cancer and autoimmune diseases in the United States. The gross profit ratio is 1.00 reflecting the efficiency of the company's production and sales operations. The cost of revenue for the company is $0.00 showcasing its production and operational expenses. The financial data pertains to the fiscal year 2024 providing a clear picture of its economic performance. The company incurred an interest expense of $0.00 reflecting its debt servicing obligations. Additionally, the total costs and expenses for the company are $86,288,000.00 reflecting its overall spending. Shattuck Labs' lead product candidate, SL-172154, is currently undergoing a Phase 1 clinical trial aimed at treating ovarian, fallopian tube, and peritoneal cancers, while another candidate, SL-279252, is also in a Phase 1 trial for advanced solid tumors and lymphoma. Established in 2016, Shattuck Labs is headquartered in Austin, Texas. With a market capitalization of $37,091,448.00 the company is classified as a small-cap player, making it an interesting opportunity for investors. The stock is affordable at $0.77 suitable for budget-conscious investors looking for entry points in the market. The stock has an average trading volume of 214,630.00 indicating moderate liquidity, which can appeal to those interested in active trading. As a key player in the Biotechnology industry, Shattuck Labs contributes significantly to the overall market landscape, driving innovation and growth in the field of biotechnology. It belongs to the Healthcare sector, where advancements are critical for addressing unmet medical needs and improving patient outcomes.
Investing in Shattuck Labs, Inc. (STTK) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bearish outlook. Always conduct your own research before investing.
Analysts predict Shattuck Labs, Inc. stock to fluctuate between $0.69 (low) and $4.99 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-07-11, Shattuck Labs, Inc.'s market cap is $37,091,448, based on 47,903,200 outstanding shares.
Compared to Meta Platforms, Inc. Class A Common Stock, Shattuck Labs, Inc. has a Lower Market-Cap, indicating a difference in performance.
To buy Shattuck Labs, Inc. (STTK) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for STTK. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Revenue: $5,721,000 | EPS: -$1.49 | Growth: -27.32%.
Visit https://www.shattucklabs.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $59.57 (2021-02-01) | All-time low: $0.69 (2025-04-07).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present at and participate in one-on-one meetings at the 24th Annual Needham Virtual Healthcare Conference, taking place April 7–10, 2025.
globenewswire.com
AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming oral presentation at the 20th Congress of ECCO in Inflammatory Bowel Diseases 2025 being held in Berlin, Germany from February 19–22, 2025. This presentation will feature results from the IND-enabling toxicology studies of SL-325, a first-in-class DR3 blocking antibody, in non-human primates.
globenewswire.com
AUSTIN, TX and DURHAM, NC, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming poster presentation at the 2025 Crohn's and Colitis Congress being held in San Francisco, California from February 6–8, 2025.
globenewswire.com
AUSTIN, TX and DURHAM, NC, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present a corporate update and participate in one-on-one meetings at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, California on January 13-16, 2025.
globenewswire.com
AUSTIN, TX and DURHAM, NC, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced a corporate update and highlighted upcoming key milestones anticipated in 2025.
accesswire.com
NEW YORK CITY, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accesswire.com
NEW YORK CITY, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accesswire.com
NEW YORK CITY, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
prnewswire.com
NEW YORK , Nov. 10, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ: STTK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accesswire.com
NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
See all news